Welcome to our dedicated page for Summit Therapeutics news (Ticker: SMMT), a resource for investors and traders seeking the latest updates and insights on Summit Therapeutics stock.
Summit Therapeutics Inc. (NASDAQ: SMMT) is a biopharmaceutical oncology company whose news flow is closely tied to the development of its lead investigational therapy, ivonescimab (SMT112 in Summit’s territories). Ivonescimab is described by the company as a potential first-in-class bispecific antibody targeting PD-1 and VEGF in a single molecule, and it is being evaluated in multiple Phase III clinical trials in non-small cell lung cancer (NSCLC) and colorectal cancer (CRC).
News about Summit frequently covers clinical milestones for ivonescimab, including updates from the global Phase III HARMONi trial in EGFR-mutated NSCLC after third-generation EGFR TKI therapy, as well as HARMONi-3 and HARMONi-7 in first-line metastatic NSCLC and HARMONi-GI3 in first-line unresectable metastatic CRC. Company announcements have highlighted progression-free survival and overall survival data, hazard ratios, response rates, and safety profiles, along with presentations at major conferences such as the World Conference on Lung Cancer, SITC, and ESMO.
Investors following SMMT news will also see regulatory and corporate updates, including Summit’s submission of a Biologics License Application to the U.S. FDA for ivonescimab plus chemotherapy in EGFR-mutated NSCLC, Fast Track designation for the HARMONi setting, and summaries of Akeso’s HARMONi-A trial in China, which demonstrated a statistically significant overall survival benefit for ivonescimab plus chemotherapy versus chemotherapy alone.
Additional news items cover financing activities such as private placements and at-the-market offerings, inducement stock option grants under Nasdaq Listing Rule 5635(c)(4), and collaboration announcements. Notably, Summit has reported a clinical trial collaboration with GSK plc to evaluate ivonescimab in combination with GSK’s investigational B7-H3-targeting antibody-drug conjugate, risvutatug rezetecan (GSK’227), across multiple solid tumor settings including small cell lung cancer.
For readers tracking SMMT, the news stream provides insight into Summit’s late-stage oncology pipeline, regulatory interactions, capital-raising efforts, and partnerships that shape the company’s development path.
Summit Therapeutics (NASDAQ: SMMT) has announced it will host an earnings conference call to discuss its fourth quarter and full year 2024 financial results on Monday, February 24, 2025, before market opening. The company will also provide an operational update during the call, which is scheduled for 9:00am ET. The event will be accessible through a live webcast on Summit's website (www.smmttx.com), and an archived version will be made available afterward.
Summit Therapeutics (NASDAQ: SMMT) has announced the granting of inducement stock options to nine new employees. The awards consist of options to purchase up to 116,725 shares of common stock, with an exercise price of $19.08 per share, based on the closing price on February 11, 2025.
The options have a ten-year term and will vest in equal annual installments over a four-year period. These inducement awards were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and were approved by Summit's Compensation Committee from an equity incentive pool reserved on May 3, 2024.
Summit Therapeutics (NASDAQ: SMMT) has announced the granting of inducement stock options to nine new employees. The awards total 145,550 shares of common stock and were granted on January 10, 2025, with an exercise price of $17.85 per share, matching the closing price on the grant date.
The options have a ten-year term and will vest in equal annual installments over four years. These awards were granted from an equity incentive pool specifically reserved for new employee inducements, as approved by the Company's Compensation Committee on May 3, 2024, in accordance with Nasdaq Listing Rule 5635(c)(4).
Summit Therapeutics (NASDAQ: SMMT) has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco. The presentation is scheduled for Monday, January 13, 2025, at 3:00 PM PT.
Chairman and CEO Robert W. Duggan and CEO & President Dr. Maky Zanganeh will deliver a corporate overview and provide updates on the company's progress, with particular focus on their innovative investigational bispecific antibody, ivonescimab.
The presentation will be accessible live through Summit's website (www.smmttx.com), with an archived version available for viewing after the event.
Summit Therapeutics (NASDAQ: SMMT) has announced the granting of inducement stock options to six new employees. The awards total 98,000 shares of common stock, with an exercise price of $17.97 per share, based on the closing price on December 10, 2024. These ten-year options, approved by the Company's Compensation Committee, will vest in equal annual installments over four years. The grants were made from a pre-approved equity incentive pool established on May 3, 2024, in accordance with Nasdaq Listing Rule 5635(c)(4).
Summit Therapeutics (NASDAQ: SMMT) announced its participation in two major healthcare conferences in Miami. The company will present at the 7th Annual Evercore HealthCONx Conference on December 3, 2024, and Citi's 2024 Global Healthcare Conference on December 4, 2024, both at 8:45am ET.
The management team will conduct fireside chats focusing on the development of their investigational bispecific antibody, ivonescimab. Both presentations will be accessible live through Summit's website and will remain available in archived form afterward.
Summit Therapeutics (NASDAQ: SMMT) has granted inducement awards of stock options to 15 new employees. The options allow for the purchase of up to 227,600 shares of common stock at an exercise price of $18.31 per share, matching the closing price on November 15, 2024. These ten-year options will vest in equal annual installments over four years. The grants were made in accordance with Nasdaq Listing Rule 5635(c)(4) and were approved by the Company's Compensation Committee from an equity incentive pool reserved on May 3, 2024.
Summit Therapeutics (NASDAQ: SMMT) reported significant progress in Q3 2024, highlighted by their lead drug ivonescimab achieving a 49% reduction in disease progression or death compared to pembrolizumab in first-line PD-L1 positive advanced NSCLC. The company completed enrollment in the global Phase III HARMONi trial, received FDA Fast Track Designation, and plans to expand the HARMONi-3 trial to include non-squamous histology patients. Summit raised $235 million in private financing, ending Q3 with $487 million in cash. Financial results showed GAAP net loss of $56.3 million ($0.08 per share) and increased R&D expenses to $37.7 million, reflecting expanded clinical development activities.
Nuvectis Pharma (NASDAQ: NVCT) showcased promising results at the AACR-NCI-EORTC Symposium, where its drug candidate NXP900 demonstrated strong synergy with ALK inhibitors in resistant non-small cell lung cancer (NSCLC) cells. The drug effectively targets SRC/YES1 kinases, addressing resistance mechanisms in cancer treatment.
The company is also anticipating data updates from NXP800's Phase 1b study in platinum-resistant, ARID1a-mutated ovarian cancer. With a current market valuation of approximately $150 million, Nuvectis is positioning itself alongside industry players like Summit Therapeutics ($15B) and Nuvalent ($6.6B) in the precision oncology space.
Summit Therapeutics (NASDAQ: SMMT) has announced it will host an earnings conference call on Wednesday, October 30, 2024, before market opening. The call, scheduled for 9:00am ET, will cover the company's third quarter 2024 financial results and provide an operational update. The event will be accessible through a live webcast on Summit's website, with an archived version available afterward.